Analysts expect Heron Therapeutics, Inc. (NASDAQ:HRTX) to post earnings per share of ($0.87) for the current fiscal quarter, according to Zacks. Three analysts have provided estimates for Heron Therapeutics’ earnings, with the highest EPS estimate coming in at ($0.82) and the lowest estimate coming in at ($0.90). Heron Therapeutics posted earnings of ($1.24) per share during the same quarter last year, which would indicate a positive year over year growth rate of 29.8%. The firm is scheduled to announce its next earnings report on Tuesday, November 14th.

According to Zacks, analysts expect that Heron Therapeutics will report full-year earnings of ($3.49) per share for the current financial year, with EPS estimates ranging from ($3.57) to ($3.36). For the next financial year, analysts expect that the business will report earnings of ($2.40) per share, with EPS estimates ranging from ($3.52) to ($1.56). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of research analysts that follow Heron Therapeutics.

Heron Therapeutics (NASDAQ:HRTX) last released its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.90) by $0.10. The business had revenue of $8.51 million during the quarter, compared to analyst estimates of $4.53 million.

Several equities research analysts recently commented on HRTX shares. ValuEngine upgraded shares of Heron Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, June 22nd. Cantor Fitzgerald reiterated an “overweight” rating on shares of Heron Therapeutics in a research report on Monday, June 26th. Zacks Investment Research upgraded shares of Heron Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price objective on the stock in a research report on Wednesday, July 12th. Jefferies Group LLC reissued a “buy” rating and set a $26.00 target price on shares of Heron Therapeutics in a research note on Friday, July 14th. Finally, Aegis reissued a “buy” rating and set a $33.00 target price on shares of Heron Therapeutics in a research note on Tuesday, July 18th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average price target of $30.20.

Several institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC grew its holdings in shares of Heron Therapeutics by 2.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock valued at $470,000 after acquiring an additional 771 shares in the last quarter. Schwab Charles Investment Management Inc. raised its holdings in shares of Heron Therapeutics by 0.6% during the second quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after acquiring an additional 1,026 shares in the last quarter. Legal & General Group Plc raised its holdings in shares of Heron Therapeutics by 13.9% during the first quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 1,098 shares in the last quarter. HighTower Advisors LLC raised its holdings in shares of Heron Therapeutics by 11.4% during the second quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock worth $231,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Tudor Investment Corp ET AL raised its holdings in shares of Heron Therapeutics by 10.2% during the second quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock worth $258,000 after acquiring an additional 1,724 shares in the last quarter.

Heron Therapeutics (NASDAQ HRTX) traded up 0.59% during trading on Friday, reaching $17.00. The company had a trading volume of 1,356,888 shares. The stock has a 50 day moving average price of $15.82 and a 200 day moving average price of $15.08. The firm’s market capitalization is $920.35 million. Heron Therapeutics has a 12 month low of $12.21 and a 12 month high of $20.85.

ILLEGAL ACTIVITY WARNING: This story was first posted by Watch List News and is owned by of Watch List News. If you are viewing this story on another website, it was copied illegally and reposted in violation of U.S. and international copyright law. The original version of this story can be read at https://www.watchlistnews.com/zacks-brokerages-anticipate-heron-therapeutics-inc-hrtx-to-post-0-87-earnings-per-share/1608499.html.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Get a free copy of the Zacks research report on Heron Therapeutics (HRTX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.